Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

KROPPENS HUS AUTORISEREDE FYSIOTERAPEUTER ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Bankruptcy risk for industry   0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6%   Bankruptcy risk   1.5% 1.4% 2.3% 2.0% 4.0% 1.9% 6.3% 6.0%   Credit score (0-100)   78 78 63 68 49 69 37 39   Credit rating   A A BBB A BBB A BBB BBB   Credit limit (kDKK)   30.6 48.9 0.1 0.7 0.0 1.2 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   8,457 7,361 7,968 8,147 9,661 9,098 0.0 0.0   EBITDA   912 1,333 1,401 1,525 3,250 2,732 0.0 0.0   EBIT   549 966 1,051 1,199 2,928 2,416 0.0 0.0   Pre-tax profit (PTP)   556.2 952.4 1,027.9 1,200.1 2,920.2 2,421.9 0.0 0.0   Net earnings   433.3 731.0 809.0 934.0 2,274.7 1,884.4 0.0 0.0   Pre-tax profit without non-rec. items   556 952 1,028 1,200 2,920 2,422 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Tangible assets total   395 302 219 179 131 160 0.0 0.0   Shareholders equity total   3,574 4,305 1,814 2,748 2,323 3,407 1,127 1,127   Interest-bearing liabilities   74.5 0.0 0.0 0.0 0.0 0.6 612 612   Balance sheet total (assets)   5,677 7,142 4,544 4,573 4,823 5,425 1,739 1,739   Net Debt   -605 -2,816 -310 -489 -1,201 -1,368 612 612     See the entire balance sheet 1000.0 Volume  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   8,457 7,361 7,968 8,147 9,661 9,098 0.0 0.0   Gross profit growth   11.0% -13.0% 8.2% 2.2% 18.6% -5.8% -100.0% 0.0%   Employees   15 14 13 13 13 11 0 0   Employee growth %   15.4% -6.7% -7.1% 0.0% 0.0% -15.4% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   5,677 7,142 4,544 4,573 4,823 5,425 1,739 1,739   Balance sheet change%   -2.3% 25.8% -36.4% 0.6% 5.5% 12.5% -67.9% 0.0%   Added value   912.1 1,332.9 1,401.1 1,524.7 3,253.7 2,732.2 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -365 -713 -685 -618 -622 -540 -160 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   4.0 5.0 5.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   6.5% 13.1% 13.2% 14.7% 30.3% 26.6% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   9.8% 15.2% 18.0% 26.4% 62.3% 47.5% 0.0% 0.0%   ROI %   12.5% 21.1% 28.4% 41.5% 96.2% 74.7% 0.0% 0.0%   ROE %   11.8% 18.6% 26.4% 41.0% 89.7% 65.8% 0.0% 0.0%   1000.0 Solidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Equity ratio %   63.9% 60.9% 39.9% 60.1% 48.2% 62.8% 64.8% 64.8%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -66.4% -211.3% -22.2% -32.1% -37.0% -50.1% 0.0% 0.0%   Gearing %   2.1% 0.0% 0.0% 0.0% 0.0% 0.0% 54.3% 54.3%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   3.0% 58.3% 0.0% 0.0% 0.0% 4,051.6% 0.0% 0.0%   1000.0 Liquidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Quick Ratio   1.7 2.1 0.8 1.5 1.2 2.1 0.0 0.0   Current Ratio   1.7 2.0 0.8 1.6 1.2 2.1 0.0 0.0   Cash and cash equivalent   679.8 2,816.0 310.5 489.4 1,201.0 1,368.4 0.0 0.0   1000.0 Capital use efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   855.1 1,964.0 -447.3 709.3 492.4 1,727.0 -305.9 -305.9   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   61 95 108 117 250 248 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   61 95 108 117 250 248 0 0   EBIT / employee   37 69 81 92 225 220 0 0   Net earnings / employee   29 52 62 72 175 171 0 0